
**CLAIMS**

1. A compound of Formula (1):



(1)

or a salt thereof, wherein;

X is N or $CR^2$;

Y is N, $NR^3$ or $CR^2$;

Z is N or $NR^3$;

wherein one but not both of Y and Z is $NR^3$;

Q is selected from $-CR^4R^5-$, $-CR^4R^5CR^6R^7-$, $-CR^4R^5CR^6R^7CR^8R^9-$, $-CR^4R^5CR^6R^7O-$, $-OCR^4R^5-$ and $-OCR^4R^5CR^6R^7-$;

$R^1$ is H, $C_{1-6}$ alkyl optionally substituted with 1 to 6 fluorine atoms, $C_{3-6}$ cycloalkyl optionally substituted with 1 to 6 fluorine atoms, a group $-C(R^{14})_2C(R^{18})_2OR^{17}$ or a group $-C(R^{14})_2C(R^{19})_2OH$, wherein each $R^{14}$ is independently H, F or $C_{1-3}$ alkyl optionally substituted with 1 to 6 fluorine atoms, $R^{17}$ is $C_{1-3}$ alkyl optionally substituted with 1 to 6 fluorine atoms, each $R^{18}$ is independently H, F or $C_{1-3}$ alkyl optionally substituted with 1 to 6 fluorine atoms and each $R^{19}$ is independently H or $C_{1-3}$ alkyl optionally substituted with 1 to 6 fluorine atoms, and wherein $R^{17}$ and one $R^{14}$ may be joined to form an oxolane or oxetane ring;

$R^2$ is H, halo, CN, $C_{1-6}$ alkyl optionally substituted with OH or 1 to 6 fluorine atoms, $C_{1-6}$ alkoxy optionally substituted with OH or 1 to 6 fluorine atoms or $C_{3-6}$ cycloalkyl optionally substituted with OH or 1 to 6 fluorine atoms, wherein one atom of the $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy or $C_{3-6}$ cycloalkyl group may be optionally replaced by a heteroatom selected from O, N, S and oxidised forms thereof;

$R^3$ is a group -V-L-W;


$R^4$, $R^5$, $R^6$, $R^7$, $R^8$ and $R^9$ are independently selected from H and $C_{1-3}$ alkyl;

wherein V is a 6-membered optionally substituted aryl or heteroaryl ring substituted with L at the meta-position relative to the position of attachment of $R^3$ to the remainder of the molecule;

L is selected from $CH_2$, CHD, $CD_2$, CHF, $CF_2$, C=O, CHOH, O and NH;

and W is an optionally substituted monocyclic or polycyclic ring system.

2. The compound according to claim 1 wherein $R^3$ is a group of the formula:




wherein, each A is independently N or $CR^{10}$;

L is selected from $CH_2$, CHD, $CD_2$, CHF, $CF_2$, C=O, CHOH, O and NH;

$R^{10}$ is selected from H, halo and $C_{1-3}$ alkyl optionally substituted with 1 to 6 fluorine atoms;

and W is either:


(i) a 6-membered optionally substituted aryl or heteroaryl ring;

or

(ii) a 9-10-membered optionally substituted heterobicyclic ring system, where one or more of the rings is aromatic.

3. The compound according to claim 1 or claim 2, wherein W is a 6-membered optionally substituted aryl or heteroaryl ring.

4. A compound according to claim 1 of Formula (1b):




(1b)

or a salt thereof, wherein;


Q is selected from $-CR^4R^5-$, $-CR^4R^5CR^6R^7-$, $-CR^4R^5CR^6R^7CR^8R^9-$, $-CR^4R^5CR^6R^7O-$, $-OCR^4R^5-$ and $-OCR^4R^5CR^6R^7-$;

$R^1$ is H, $C_{1-6}$ alkyl optionally substituted with 1 to 6 fluorine atoms, $C_{3-6}$ cycloalkyl optionally substituted with 1 to 6 fluorine atoms, a group $-C(R^{14})_2C(R^{18})_2OR^{17}$ or a group $-C(R^{14})_2C(R^{19})_2OH$, wherein each $R^{14}$ is independently H, F or $C_{1-3}$ alkyl optionally substituted with 1 to 6 fluorine atoms, $R^{17}$ is $C_{1-3}$ alkyl optionally substituted with 1 to 6 fluorine atoms, each $R^{18}$ is independently H, F or $C_{1-3}$ alkyl optionally substituted with 1 to 6 fluorine atoms and each $R^{19}$ is independently H or $C_{1-3}$ alkyl optionally substituted with 1 to 6 fluorine atoms, and wherein $R^{17}$ and one $R^{14}$ may be joined to form an oxolane or oxetane ring;

$R^2$ is H, halo, CN, $C_{1-6}$ alkyl optionally substituted with OH or 1 to 6 fluorine atoms, $C_{1-6}$ alkoxy optionally substituted with OH or 1 to 6 fluorine atoms or $C_{3-6}$ cycloalkyl optionally substituted with OH or 1 to 6 fluorine atoms, wherein one atom of the $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy or $C_{3-6}$ cycloalkyl group may be optionally replaced by a heteroatom selected from O, N, S and oxidised forms thereof;

$R^4$, $R^5$, $R^6$, $R^7$, $R^8$ and $R^9$ are independently selected from H and $C_{1-3}$ alkyl;

$R^3$ is a group of the formula:




wherein, each A is independently N or $CR^{10}$;


L is selected from $CH_2$, CHD, $CD_2$, CHF, $CF_2$, C=O, CHOH, O and NH;

each B is independently N, $CR^{11}$, $CR^{12}$, $CR^{13}$, $CR^{15}$ or $CR^{16}$;


$R^{10}$ is selected from H, halo and $C_{1-3}$ alkyl optionally substituted with 1 to 6 fluorine atoms;

$R^{11}$, $R^{12}$, $R^{13}$, $R^{15}$ and $R^{16}$ are independently selected from H, CN, $SF_5$, halo, a $C_{1-6}$ saturated hydrocarbon group optionally substituted with 1 to 6 fluorine atoms wherein one atom of the $C_{1-6}$ saturated hydrocarbon group is optionally replaced by a heteroatom selected from O, N, S and oxidised forms thereof, $OC_{1-6}$ alkyl optionally substituted with 1 to 6 fluorine atoms, $SO_2C_{1-6}$ alkyl optionally substituted with 1 to 6 fluorine atoms and $C_{3-6}$ cycloalkyl optionally substituted with 1 to 6 fluorine atoms or optionally substituted with $CF_3$.


5. The compound according to claim 1, which is a compound of formula (2a), (2b), (2c), (2d), (2e), (2f) or (2g):







(2a);





(2b);





(2c);


(2d);

(2e);

(2f);


(2g);


or a salt thereof.

6. The compound according to claim 1, which is a compound of formula (11a):


(11a)

or a salt thereof.

7. The compound according to any one of claims 1 to 6 wherein $R^3$ is a group of the formula:



wherein, each A is independently N or $CR^{10}$;

L is selected from $CH_2$, CHD, $CD_2$, CHF, $CF_2$, C=O, CHOH, O and NH;


each B is independently N, $CR^{11}$, $CR^{12}$, $CR^{13}$, $CR^{15}$ or $CR^{16}$;

$R^{10}$ is selected from H, halo and $C_{1-3}$ alkyl optionally substituted with 1 to 6 fluorine atoms;

$R^{11}$, $R^{12}$, $R^{13}$, $R^{15}$ and $R^{16}$ are independently selected from H, CN, $SF_5$, halo, a $C_{1-6}$ saturated hydrocarbon group optionally substituted with 1 to 6 fluorine atoms wherein one atom of the $C_{1-6}$ saturated hydrocarbon group is optionally replaced by a heteroatom selected from O, N, S and oxidised forms thereof, $OC_{1-6}$ alkyl optionally substituted with 1 to 6 fluorine atoms, $SO_2C_{1-6}$ alkyl optionally substituted with 1 to 6


fluorine atoms and $C_{3-6}$ cycloalkyl optionally substituted with 1 to 6 fluorine atoms or optionally substituted with $CF_3$.

8. The compound according to claim 7, wherein $R^3$ is selected from the group consisting of:




9. The compound according to any one of claims 1 to 8, wherein L is $CH_2$.

10. The compound according to any one of claims 7 to 9, wherein the group:













is selected from the group consisting of:



11. The compound according to any one of claims 1 to 10, wherein Q is selected from the group consisting of $-CH_2CH_2-$; $-CH_2CH_2CH_2-$; $-CH_2-$; $-OCH_2-$; $-CH_2CH_2O-$, $-CH(CH_3)CH_2-$ and $-CH_2CH(CH_3)-$.

12. The compound according to claim 11, wherein Q is $-CH_2CH_2-$.

13. The compound according to claim 1 which is a compound of formula (13a), (13b), (13c), (13d), (13e), (13f), (13g), (13h), (13i) or (13j):


(13a);

(13b);

(13c);

(13d);

(13e);

(13f);

(13g);

(13h);

(13i);

(13j);


or a salt thereof, wherein;

$R^1$ is H, $C_{1-6}$ alkyl optionally substituted with 1 to 6 fluorine atoms, $C_{3-6}$ cycloalkyl optionally substituted with 1 to 6 fluorine atoms, a group $-C(R^{14})_2C(R^{18})_2OR^{17}$ or a group $-C(R^{14})_2C(R^{19})_2OH$, wherein each $R^{14}$ is independently H, F or $C_{1-3}$ alkyl optionally substituted with 1 to 6 fluorine atoms, $R^{17}$ is $C_{1-3}$ alkyl optionally substituted with 1 to 6 fluorine atoms, each $R^{18}$ is independently H, F or $C_{1-3}$ alkyl optionally substituted with 1 to 6 fluorine atoms and each $R^{19}$ is independently H or $C_{1-3}$ alkyl optionally substituted with 1 to 6 fluorine atoms, and wherein $R^{17}$ and one $R^{14}$ may be joined to form an oxolane or oxetane ring;

$R^2$ is H, halo, CN, $C_{1-6}$ alkyl optionally substituted with OH or 1 to 6 fluorine atoms, $C_{1-6}$ alkoxy optionally substituted with OH or 1 to 6 fluorine atoms or $C_{3-6}$ cycloalkyl optionally substituted with OH or 1 to 6 fluorine atoms, wherein one atom of the $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy or $C_{3-6}$ cycloalkyl group may be optionally replaced by a heteroatom selected from O, N, S and oxidised forms thereof;

$R^{11}$, $R^{12}$, $R^{13}$, $R^{15}$ and $R^{16}$ are independently selected from H, CN, $SF_5$, halo, a $C_{1-6}$ saturated hydrocarbon group optionally substituted with 1 to 6 fluorine atoms wherein one atom of the $C_{1-6}$ saturated hydrocarbon group is optionally replaced by a heteroatom selected from O, N, S and oxidised forms thereof, $OC_{1-6}$ alkyl optionally substituted with 1 to 6 fluorine atoms, $SO_2C_{1-6}$ alkyl optionally substituted with 1 to 6 fluorine atoms and $C_{3-6}$ cycloalkyl optionally substituted with 1 to 6 fluorine atoms or optionally substituted with $CF_3$.

14. The compound according to claim 16 which is a compound of formula (6a):




(6a)

or a salt thereof.

15. The compound according to any one of claims 1 to 14, wherein $R^1$ is H, methyl, $-CH_2CH_2OCH_3$ or $-CH_2CH_2OH$.

16. The compound according to any one of claims 1 to 4 or 13 to 15 wherein $R^2$ is selected from H, methyl, F, Cl, CN, $CF_3$ and $CH_2OH$.

17. The compound according to claim 16 wherein $R^2$ is H or methyl.

18. The compound according to any one of claims 4 to 17, wherein $R^{11}$, $R^{12}$, $R^{13}$, $R^{15}$ and $R^{16}$ are independently selected from H, CN, F, Cl, methyl, isopropyl, cyclopropyl, $CF_3$, $CF_2H$, $OCF_2H$, OMe and .

19. The compound according to claim 18, wherein $R^{11}$, $R^{12}$, $R^{13}$, $R^{15}$ and $R^{16}$ are independently selected from H, F and $CF_3$.

20. The compound according to claim 1 which is selected from the group consisting of:

1-(2-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(4-(3-(trifluoromethyl)benzyl)pyridin-2-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

5-methyl-1-(4-(3-(trifluoromethyl)benzyl)pyridin-2-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(4-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-2-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(4-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-2-yl)-5-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(4-((6-fluoro-5-methylpyridin-3-yl)methyl)pyridin-2-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(4-((6-fluoro-5-methylpyridin-3-yl)methyl)pyridin-2-yl)-5-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

2-(4-(3-(trifluoromethyl)benzyl)pyridin-2-yl)-2,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

2-(2-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-2,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(4-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-2-yl)-5,6,7,8-tetrahydropyrazolo[4,3-*c*]azepin-4(1*H*)-one;

1-(4-(3-(trifluoromethyl)benzyl)pyridin-2-yl)-5,6,7,8-tetrahydropyrazolo[4,3-*c*]azepin-4(1*H*)-one;

1-(2-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-5,6,7,8-tetrahydropyrazolo[4,3-*c*]azepin-4(1*H*)-one;

1-(4-(3-(trifluoromethyl)benzyl)pyridin-2-yl)-6,7-dihydro-1*H*-pyrazolo[4,3-*f*][1,4]oxazepin-4(5*H*)-one;

1-(4-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-2-yl)-6,7-dihydro-1*H*-pyrazolo[4,3-*f*][1,4]oxazepin-4(5*H*)-one;

1-(5-(3-fluoro-5-(trifluoromethyl)benzyl)pyridazin-3-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(5-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-3-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(6-(3-fluoro-5-(trifluoromethyl)benzyl)pyridazin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-{4-[3-fluoro-5-(trifluoromethyl)phenoxy]pyridin-2-yl}-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(4-chlorobenzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-chloro-5-fluorobenzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3,5-difluorobenzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(4-fluoro-3-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3,4,5-trifluorobenzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-chloro-4-fluorobenzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-fluoro-5-methylbenzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-chloro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-methyl-5-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(2-fluoro-3-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(2-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3,5-dichlorobenzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(4-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

3-((4-(4-oxo-4,5,6,7-tetrahydro-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl)pyridin-2-yl)methyl)-5-(trifluoromethyl)benzonitrile;

1-(2-(3,5-bis(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-fluoro-5-(trifluoromethyl)benzoyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-((3-fluoro-5-(trifluoromethyl)phenyl)(hydroxy)methyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(fluoro(3-fluoro-5-(trifluoromethyl)phenyl)methyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(difluoro(3-fluoro-5-(trifluoromethyl)phenyl)methyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-((3-fluoro-5-(trifluoromethyl)phenyl)methyl-$d_2$)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-]pyridin-4-one;

1-(2-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-6-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(4-(3-(trifluoromethyl)benzyl)pyridin-2-yl)-5,6,7,8-tetrahydro-[1,2,3]triazolo[4,5-*c*]azepin-4(1*H*)-one;

1-(4-(3-(trifluoromethyl)benzyl)pyridin-2-yl)-1,5,6,7-tetrahydro-4*H*-[1,2,3]triazolo[4,5-*c*]pyridin-4-one;

2-(4-(3-(trifluoromethyl)benzyl)pyridin-2-yl)-2,5,6,7-tetrahydro-4*H*-[1,2,3]triazolo[4,5-*c*]pyridin-4-one;

5-methyl-2-(4-(3-(trifluoromethyl)benzyl)pyridin-2-yl)-2,5,6,7-tetrahydro-4*H*-[1,2,3]triazolo[4,5-*c*]pyridin-4-one;

2-(4-(3-(trifluoromethyl)benzyl)pyridin-2-yl)-5,6,7,8-tetrahydro-[1,2,3]triazolo[4,5-*c*]azepin-4(2*H*)-one;

1-(4-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-2-yl)-5,6,7,8-tetrahydro-[1,2,3]triazolo[4,5-*c*]azepin-4(1*H*)-one;

1-(4-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-2-yl)-1,7-dihydropyrazolo[4,3-*d*][1,2]oxazin-4(5*H*)-one;

1-(2-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-5,6-dihydropyrrolo[3,4-*c*]pyrazol-4(1*H*)-one;

1-(2-((3-fluoro-5-(trifluoromethyl)phenyl)methyl-*d*)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-7-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrrolo[3,2-*c*]pyridin-4-one;

1-(2-(3-fluoro-5-(trifluoromethyl)phenoxy)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-cyclopropyl-5-fluorobenzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-fluoro-4-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(4-methoxy-3-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(6-(3-fluoro-5-(trifluoromethyl)benzyl)pyrimidin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-methoxy-5-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(4-chloro-3,5-difluorobenzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(benzo[*b*]thiophen-5-ylmethyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-methoxy-4-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-fluoro-5-(pentafluoro-$\lambda^6$-sulfaneyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-(difluoromethoxy)-5-fluorobenzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(4-(difluoromethoxy)-3-fluorobenzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3,4-difluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-(difluoromethyl)-5-fluorobenzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-chloro-4,5-difluorobenzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(quinolin-3-ylmethyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(4-chloro-3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(benzo[*b*]thiophen-2-ylmethyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3,5-difluoro-4-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-fluoro-5-isopropylbenzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-((5-fluoro-6-methoxypyridin-3-yl)methyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-chloro-4-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-fluoro-5-(1-(trifluoromethyl)cyclopropyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-((6-fluoro-5-methylpyridin-3-yl)methyl)pyridin-4-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

3-methyl-1-(2-(3,4,5-trifluorobenzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

3-methyl-1-(2-(3-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-chloro-5-fluorobenzyl)pyridin-4-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-chloro-4-fluorobenzyl)pyridin-4-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(4-(difluoromethoxy)-3-fluorobenzyl)pyridin-4-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(5-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-3-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(4-((6-fluoro-5-methylpyridin-3-yl)methyl)pyridin-2-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-chloro-4,5-difluorobenzyl)pyridin-4-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

3-fluoro-5-((4-(3-methyl-4-oxo-4,5,6,7-tetrahydro-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl)pyridin-2-yl)methyl)benzonitrile;

1-(2-(3,4-difluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(4-chloro-3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-chloro-4-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-(difluoromethoxy)-5-fluorobenzyl)pyridin-4-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(4-chloro-3,5-difluorobenzyl)pyridin-4-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-(difluoromethyl)-5-fluorobenzyl)pyridin-4-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-((6-methoxypyridin-3-yl)methyl)pyridin-4-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-((5-fluoro-6-methoxypyridin-3-yl)methyl)pyridin-4-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-((6-(difluoromethoxy)pyridin-3-yl)methyl)pyridin-4-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(4-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-2-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

3-fluoro-5-((4-(4-oxo-4,5,6,7-tetrahydro-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl)pyridin-2-yl)methyl)benzonitrile;

1-(2-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-5,6,7,8-tetrahydro-[1,2,3]triazolo[4,5-*c*]azepin-4(1*H*)-one;

2-(4-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-2-yl)-2,5,6,7-tetrahydro-4*H*-[1,2,3]triazolo[4,5-*c*]pyridin-4-one;

1-(4-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-2-yl)-1,5,6,7-tetrahydro-4*H*-[1,2,3]triazolo[4,5-*c*]pyridin-4-one;

1-(2-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-[1,2,3]triazolo[4,5-*c*]pyridin-4-one;

2-(2-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-2,5,6,7-tetrahydro-4*H*-[1,2,3]triazolo[4,5-*c*]pyridin-4-one;

1-(4-(3-(difluoromethyl)-5-fluorobenzyl)pyridin-2-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(5-(3-fluoro-5-(trifluoromethyl)phenoxy)pyridin-3-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-5-(2-methoxyethyl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-5-(2-hydroxyethyl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(4-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-2-yl)-5-(2-methoxyethyl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(4-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-2-yl)-5-(2-hydroxyethyl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-fluoro-5-(trifluoromethyl)benzyl)-5-methylpyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(3-(3-fluoro-5-(trifluoromethyl)benzyl)phenyl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-((6-(difluoromethoxy)-5-fluoropyridin-3-yl)methyl)pyridin-4-yl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-((6-(difluoromethoxy)-5-fluoropyridin-3-yl)methyl)pyridin-4-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

2-(2-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-6,7-dihydro-2*H*-pyrazolo[4,3-*f*][1,4]oxazepin-4(5*H*)-one;

1-(4-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-2-yl)-3-(hydroxymethyl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-3-(hydroxymethyl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-4-oxo-4,5,6,7-tetrahydro-1*H*-pyrazolo[4,3-*c*]pyridine-3-carbonitrile;

1-(2-(3-fluoro-5-(trifluoromethyl)benzyl)pyridin-4-yl)-3-(trifluoromethyl)-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(2-((3-fluoro-5-(trifluoromethyl)phenyl)(hydroxy)methyl)pyridin-4-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

1-(4-((3-fluoro-5-(trifluoromethyl)phenyl)(hydroxy)methyl)pyridin-2-yl)-3-methyl-1,5,6,7-tetrahydro-4*H*-pyrazolo[4,3-*c*]pyridin-4-one;

or a salt thereof.

21. The compound according to any one of claims 1 to 20 having GPR52 receptor modulator activity.

22. The compound according to any one of claims 1 to 20 for use as a GPR52 receptor agonist.

23. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 22 and a pharmaceutically acceptable excipient.

24. The compound according to any one of claims 1 to 22 or composition according to claim 23 for use in medicine.

25. Use of ~~T~~the compound according to any one of claims 1 to 22 or composition according to claim 23 ~~for use~~ in the manufacture of a medicament for the treatment of psychiatric disorders; neuropsychiatric disorders; neurodegenerative disorders; psychotic disorders; cognitive disorders; neurocognitive disorders; extrapyramidal disorders; movement disorders; motor disorders; hyperkinetic movement disorders; catatonia; mood disorders; depressive disorders; anxiety disorders; obsessive-compulsive disorder (OCD); autism spectrum disorders; depressive disorders; hypothalamic disorders; pituitary disorders; prolactin-related disorders; trauma- or stressor-related disorders; disruptive, impulse-control or conduct disorders; sleep-wake disorders; substance-related disorders; addictive disorders; behavioral disorders; hypofrontality; abnormalities in the tuberoinfundibular, mesolimbic, mesocortical, or nigrostriatal pathway; decreased activity in the striatum; cortical dysfunction; neurocognitive dysfunction or conditions or symptoms related thereto.

26. The ~~compound or composition for use~~ use according to claim 25, wherein the disorder or symptom is selected from schizophrenia, depression, attention-deficit hyperactivity disorder (ADHD), generalised anxiety disorder, obsessive-compulsive disorder (OCD), panic disorder, bipolar disorder, addiction/impulse-control disorders, autism spectrum disorders, psychosis, anhedonia, agitation, Alzheimer's disease, Parkinson's disease, Huntington's disease, vascular dementia, Lewy body disease, frontotemporal dementia, Tourette's syndrome, hyperprolactinemia, pituitary adenoma, prolactinoma, craniopharyngioma, Cushing's disease, diabetes insipidus, non-functioning tumours, obesity, posttraumatic stress disorder (PTSD), akathisia and associated movements, athetosis, ataxia, ballismus, hemiballismus, chorea, choreoathetosis, dyskinesia, tardive dyskinesia, neuroleptic-induced dyskinesia, myoclonus, mirror movement disorder, paroxysmal kinesigenic dyskinesia, restless legs syndrome, spasms, stereotypic movement disorder, sterotypy, Tic disorder, tremor, Wilson's disease, schizotypal personality disorder, delusional disorder, brief psychotic disorder, schizophreniform disorder, schizoaffective disorder, substance- or medication-induced psychotic disorder, delusions, hallucinations, disorganized thinking, grossly

disorganized or abnormal motor behavior, catatonia, major depressive disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, substance- or medication-induced bipolar and related disorders, bipolar and related disorders due to another medical condition, separation anxiety disorder, selective mutism, specific phobia, social anxiety disorder, panic disorder, agoraphobia, generalized anxiety disorder, substance- or medication-induced anxiety disorder, anxiety disorders due to another medical condition, delirium, major neurocognitive disorder, minor neurocognitive disorder, amnesia, dementia, developmental coordination disorder, stereotypic movement disorder, a post-stroke effect, dentatorubral-pallidoluysian atrophy, diminished emotional expression, avolition, alogia and asociality.

27. The ~~compound or composition for~~ use according to claim 25, wherein the disorder or symptom is selected from schizophrenia, depression, attention-deficit hyperactivity disorder (ADHD), generalised anxiety disorder, obsessive-compulsive disorder (OCD), panic disorder, bipolar disorder, addiction/impulse-control disorders, autism spectrum disorders, psychosis, neurocognitive disorder, delirium, anhedonia, agitation, Alzheimer's disease, Parkinson's disease, Huntington's disease, vascular dementia, Lewy body disease, frontotemporal dementia, Tourette's syndrome, hyperprolactinemia, obesity, and posttraumatic stress disorder (PTSD).